Stockwinners Market Radar for July 16, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT Hope Bancorp authorizes $50M stock repurchase program - Hope Bancorp announced that its board has authorized the repurchase of up to $50M of the company's common stock. The repurchase authorization does not have any expiration date.

18:46 EDT Novelion Therapeutics announces BC Court dismissed action filed by Whitefort - Novelion Therapeutics announced that on July 16 the Supreme Court of British Columbia issued its decision in response to the previously announced petition filed by Whitefort Capital Master Fund against Novelion, as respondent, seeking a declaration that Novelion breached section 301 of the Business Corporations Act of British Columbia in entering into a Restructuring Support Agreement, or RSA, with, among others, Aegerion Pharmaceuticals, on May 20 in connection with Aegerion's Chapter 11 plan of reorganization in the United States Bankruptcy Court, Southern District of New York Case No. 19-11632. The BC Court dismissed the action filed by Whitefort, finding that "Novelion entering into the RSA is not a transaction contemplated by s. 301" of the BCA.

18:33 EDT Domino's Pizza CEO: We are in a position of strength - In an interview on CNBC's Mad Money, Domino's Pizza CEO Richard Allison Jr. said: We gained a significant amount of market share in the pizza category in Q2... Our unit growth was quite positive... It's a tougher operating environment than in years past and we have new competitors... There are labor pressures currently... Our franchisees are really healthy and we are focused on their profitability... We are positioned quite well relative to the restaurant industry... We still have a very healthy business model... We are gaining share at a significant pace in the International markets.

17:45 EDT SPDR Gold Shares holdings fall from 800.54MT to 799.37MT - This is the lowest level of holdings since July 9th.

17:24 EDT Mallinckrodt falls over 10% to $7.36 per share after halting Acthar gel trial

17:05 EDT GoDaddy Chief Accounting Officer Rebecca Morrow resigns - In a regulatory filing, GoDaddy disclosed that on July 12, Rebecca Morrow informed the company she will resign from her role as Chief Accounting Officer effective September 1. Morrow has decided to accept a position with another company and will continue to serve as the company's principal accounting officer through the effective date. Morrow and the company have no disagreements with respect to any accounting-related policy or matter.

16:54 EDT United Continental sees 2020 total aircraft deliveries of 65

16:50 EDT United Continental sees FY19 consolidated capacity growth 3%-4% y/y - Sees FY19: Consolidated CASM excluding third-party business expenses, fuel & profit sharing up 0.5%-1%; Effective income tax rate 21%-23%; Adjusted CapEx approximately $4.9B. Prior FY19 view given on 4/17: Saw FY19 consolidated capacity growth 4%-5% y/y. Saw FY19: Adjusted CASM flat; effective income tax rate 21%-23%; adjusted CapEx ~$4.7B.

16:44 EDT United Continental sees Q3 capacity growth 2%-3% y/y - Sees Q3: Adjusted pre-tax margin 10%-12%; Consolidated PRASM up 0.5%-2.5%; Consolidated CASM, excluding third party business expenses, fuel and profit sharing up 1%-2%; Consolidated average aircraft fuel price per gallon $2.12-$2.22; Effective income tax rate 21%-23%. Guidance from investor update presentation.

16:32 EDT Knight says Health Canada approves NERLYNX for early-stage breast cancer - Knight Therapeutics announced that Health Canada has approved NERLYNX for the extended adjuvant treatment of women with early-stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy. Knight has the exclusive right to commercialize NERLYNX in Canada under a license agreement with Puma Biotechnology, Inc.

16:22 EDT Internap to streamline organization, initiates search for new CFO - Internap announced that Joseph DuFresne, Vice President, Corporate Development is being promoted to Senior Vice President, Finance, Corporate Development and Treasury, effective immediately. Jim Keeley, INAP's CFO, has announced his planned departure from INAP on August 30, 2019 for a new opportunity with a private company. The Board has initiated a search for a new CFO and intends to appoint DuFresne to the additional role of Interim Chief Financial Officer, effective August 30, 2019, pending the Board's appointment of a permanent CFO. "The entire Board of Directors joins me in thanking Jim for his significant contributions to INAP over the past year," said Peter D. Aquino, President and Chief Executive Officer. "Jim's strong financial leadership and data center experience were instrumental in effecting our transformation to the new INAP, and we wish Jim the best. Going forward, we are further streamlining the organization as we evaluate our opportunities to drive shareholder value. I am very excited about Joe DuFresne's expanded new role at INAP. Joe's financial background, experience and financial acumen will be invaluable to INAP as we continue with INAP 2.0 and our strategic plans. I have confidence in Joe's leadership in moving us through this transition as interim and in the strength of our accounting and finance team while we search for Jim's replacement."

16:19 EDT Whiting Petroleum names Correne S. Loeffler CFO - Whiting Petroleum announced that Correne S. Loeffler has been named Chief Financial Officer effective August 1, 2019. Loeffler previously served as Vice President, Finance and Treasurer for Callon Petroleum Company. Loeffler succeeds Michael J. Stevens, who is stepping down after an 18-year career with Whiting. Stevens was named Chief Financial Officer in 2005 and will depart effective August 1, 2019.

16:19 EDT CSX Q2 CapEx down to $769M from $823M in Q218

16:18 EDT United Continental authorizes new $3B share repurchase program

16:18 EDT United Continental reports Q2 total passenger revenue up 6.1% y/y - Consolidated second-quarter passenger revenue per available seat mile increased 2.5% year-over-year. Consolidated second-quarter unit cost per available seat mile decreased 0.4% year-over-year. Consolidated second-quarter CASM, excluding special charges, third-party business expenses, fuel and profit sharing, increased 0.6% year-over-year.

16:16 EDT CSX says merchandise growth 'offset' intermodal weakness - Chemicals increased as stronger crude oil and waste shipments were partially offset by reduced fly ash, natural gas liquids and sand volumes. Automotive driven by strength in trucks and SUVs. Agricultural & Food Products growth driven by strength in domestic grain and ethanol markets.Forest Products increase led by high demand for wood pulp and stronger lumber shipments. Minerals strength driven by increased construction and paving project activity. Metals and Equipment declined as a result of decreased metal shipments, primarily in sheet steel, construction and scrap markets

16:13 EDT CSX reports Q2 operating ratio fell to 57.4% since Q2 last year - Last year's Q2 operating ratio 58.6%.

16:09 EDT Inovio to reduce annual burn rate by 25% and workforce by 28% - Inovio Pharmaceuticals announced plan to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market product candidates. The company has cut selected early-stage R&D programs and discontinued further development of its Phase 1/2 study in advanced bladder cancer, while reducing its annual burn rate by 25% and its workforce by 28%. Realignment enables Inovio to focus on: First, commercializing the lead asset VGX-3100, a novel DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus; second, re-deploying resources to rapidly advance INO-3107 to treat RRP; third, partnership with AstraZeneca to advance MEDI0457 in combination with AstraZeneca's checkpoint inhibitor in HPV-related cancers, including the ongoing Phase 2 study for treatment of head and neck cancer; fourth, INO-5401 development efforts on treating GBM, while discontinuing its Phase 1/2 study of INO-5401 in advanced bladder cancer; and finally, accelerating the clinical development of its transformative dBTE which generated potent cancer-killing activities in a preclinical study and which build on recent advances of its innovative and high-value dMAb(TM) (DNA-encoded monoclonal antibody) technology.

16:07 EDT Einhorn's Greenlight reports 9.0% stake in NeuBase Therapeutics - David Einhorn's Greenlight Capital disclosed a 9.0% stake in NeuBase Therapeutics, which represents 1,538,462 shares. The filing does not allow for activism.

16:04 EDT Seattle Genetics backs FY19 Adcetris net product sales view of $610M-$640M

16:01 EDT Arrowhead receives orphan drug designation for ARO-ANG3 - Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia. ARO-ANG3 is a subcutaneously administered RNA interference-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias, such as HoFH, and metabolic diseases. The company began dosing ARO-ANG3 in a first-in-human study in January 2019. AROANG1001 is a Phase 1 single and multiple dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-ANG3 in adult healthy volunteers and patients with dyslipidemia. The study is designed to enroll up to 70 subjects. HoFH is a rare inherited disorder of lipoprotein metabolism. It is a life-threatening disease, characterized by marked elevation of low-density lipoprotein cholesterol leading to premature cardiovascular disease. Without adequate treatment, cholesterol buildup in the arterial wall leads to early atherosclerosis and cardiovascular disease, even in childhood.

15:08 EDT CBS says AT&T 'continues to propose unfair terms' - CBS (CBS) issued a statement on DirectTV and AT&T (T) U-verse TV negotiations, stating in part: "CBS Corporation, owner of America's Most Watched Network, is negotiating resolutely and in good faith with DIRECTV, DIRECTV NOW and AT&T U-verse TV to reach a fair market value agreement for its programming. CBS has reached timely, fair agreements with hundreds of other cable, satellite, telco and internet providers to carry our industry-leading, fan-favorite programming. AT&T, however, continues to propose unfair terms well below those agreed to by its competitors and may drop CBS unless we agree to those terms. CBS would like to avoid being dropped, but unless an agreement is reached, our viewers should be prepared for DIRECTV and AT&T U-verse TV to remove CBS-owned television stations in New York, Los Angeles, Chicago, Philadelphia, Dallas, San Francisco, Boston, Atlanta, Tampa, Seattle, Detroit, Minneapolis, Miami, Denver, Sacramento, Pittsburgh and Baltimore at 11:00 PM, PT on July 19. DIRECTV NOW customers nationwide would lose the CBS Television Network's hit programming as well." Reference Link

14:38 EDT Federal Reserve approves Chemical Financial deal to acquire TCF Financial - The Federal Reserve Board announced its approval of the application under section 3 of the Bank Holding Company Act of 1956 by Chemical Financial (CHFC) to acquire TCF Financial Corporation (TCF) and thereby indirectly acquire its subsidiary bank, TCF National Bank, Sioux Falls, South Dakota.Reference Link

14:04 EDT McDonald's adds DoorDash as U.S. delivery partner - McDonald's USA and DoorDash announced a new partnership to expand the availability and accessibility of "McDelivery" beyond its current offering, launching first in the Houston, Texas area across more than 200 restaurants beginning July 29. McDonald's will also be a part of DashPass, DoorDash's subscription program. "McDelivery launched in the US in 2017, with partners including Uber Eats, and globally has grown to a $3 billion business for both McDonald's and franchise restaurants. McDelivery is now available in over 9,000 restaurants in the US, which is more than half of all McDonald's US restaurants," the company stated.

13:20 EDT Toyota to consider options after Hogan lawsuit verdict - Toyota issued a statement after a jury in California Superior Court, in a case brought by two California dealerships owned by Roger Hogan, found Toyota not liable for plaintiffs' allegations of fraud by concealment, including those involving Prius inverter safety issues alleged by the plaintiffs. The jury did find Toyota liable for the claims of breach of the implied covenant of good faith and fair dealing, awarding approximately $15.8M in total damages, but awarding no punitive damages, the company pointed out. Toyota said, "To be clear, this lawsuit originated from a business dispute Roger Hogan had with Toyota over management and succession issues involving his dealership, not the effectiveness of the Prius inverter recalls. Despite claims by plaintiffs' counsel and subsequent misleading and erroneous reporting starting with the Los Angeles Times, neither the verdict form nor the jury's decision in the Hogan matter indicated that the finding on breach of good faith and fair dealing was in any way related to vehicle safety issues...While we respect the jury's decision, we remain confident the evidence and testimony clearly demonstrated that Toyota abided by its contractual obligations to the Roger Hogan dealerships and has been transparent with its dealers, regulators and customers regarding the vehicle issues raised at trial. We will consider our options moving forward." Reference Link

13:14 EDT Konami grabs exclusive video game rights to Juventus for 'PES' - Japanese game developer Konami announced a long-term, exclusive partnership with Juventus FC, current Italian champions and globally recognised football brand. The partnership between Konami and Juventus FC provides the "eFootball PES" series creators with exclusive use of Juventus FC within console football video games, including the team name, crest and official kits. In addition, the development team has been granted in-depth access to the players themselves to recreate their likenesses in the new game as accurately as possible, the company said. Blog Realsport101 noted that, as Juventus will be exclusive to "PES," EA's (EA) upcoming soccer sim "FIFA 20" will not feature the team or its stadium. The Fly notes that "PES" stands for "Pro Evolution Soccer." Reference Link

13:04 EDT Arrowhead homozygous familial hypercholesterolemia treatment given orphan status - Arrowhead Pharmaceuticals' treatment of homozygous familial hypercholesterolemia was granted FDA orphan designation, according to a post to the agency's website. Reference Link

12:53 EDT CareDx falls after analyst says AlloSure 'mostly useless' as kidney diagnostic - Shares of transplant diagnostics company CareDx (CDNA) are falling after an earlier report from Sahm Adrangi of Kerrisdale Capital. KERRISDALE SHORT THESIS: Adrangi said in the report that Kerrisdale is short CareDx due to the fact that "share price has increased by 30x over just the last two years and now trades at over 18x sales. The meteoric rise and generous valuation have come in the wake of excitement over the commercialization of AlloSure, a blood test intended to identify organ rejection in kidney transplant recipients." Kerrisdale believes that "AlloSure is mostly useless, and potentially dangerous if used improperly. It should be obvious that a diagnostic test for transplant rejection that misses about 40% of rejections compared to the current standard of care has little place in clinical practice." ANALYST VIEW: Less than a week ago, Craig-Hallum analyst Per Ostlund raised his price target for CareDx to $48 from $40 after President Trump signed an executive order to remake kidney care in the U.S., laying out a series of initiatives that clearly cement organ transplantation as a preferred treatment option for those suffering from kidney disease. While the initiatives will no doubt take some measure of time to translate into an increase in transplants, the analyst believes the order is an "unmitigated positive and wind at the back" for CareDx, which is involved in patient care across the transplant continuum. Ostlund reiterated a Buy rating on the shares at the time. PRICE ACTION: Shares of CareDx are down over 14%, or $5.31, to $32.09 per share in afternoon trading.

12:00 EDT Giga-tronics receives orders totaling $3.74M from Lockheed and Raytheon - Giga-tronics (GIGA) announced that it has received two orders totaling $3.74M from Lockheed Martin (LMT) and Raytheon (RTN). The orders are for Microwave Integrated Components used in airborne military applications. The company also announced preliminary operating results for the first quarter of fiscal 2020 which ended June 29, 2019. Net sales are expected to be approximately $3.5M. Operating income for the first quarter is expected to be approximately $100,000. While the orders reported above were received during the first quarter of fiscal 2020, the company recognized no revenue during the quarter with respect to these orders. The company will issue a more complete earnings release with commentary for the first quarter of fiscal 2020 and host a conference call the week of August 5.

12:00 EDT Domino's Pizza falls -7.4% - Domino's Pizza is down -7.4%, or -$19.97 to $249.95.

12:00 EDT Fortuna Silver Mines rises 12.4% - Fortuna Silver Mines is up 12.4%, or 34c to $3.12.

12:00 EDT Blue Apron rises 43.6% - Blue Apron is up 43.6%, or $3.34 to $11.00.

11:02 EDT Sabre, ARC sign agreement to streamline travel agencies' NDC transition - Airlines Reporting Corp. and Sabre Corporation recently signed a forward-looking cooperative agreement to ensure travel agencies can easily align with future airline distribution strategies. This collaboration will provide a seamless way for agencies to report and settle transactions regardless of an airline's chosen distribution model, including New Distribution Capability. The ARC-Sabre agreement modernizes a 30-year contract between the two companies for reporting and settlement services. ARC continues to work with other technology partners to help the industry move forward by ensuring accurate and trustworthy settlement services across the distribution landscape.

10:49 EDT Vornado sees 5c decrease in Q2 FFO due to certain items - Vornado Realty Trust announced that its financial results for the three months ended June 30 will include certain items, including a roughly $2.56M net gain on the transfer of its Fifth Avenue and Times Square JV and non-cash impairment losses and related write-offs due substantially all on 608 Fifth Avenue, that result in an increase in net income attributable to common shareholders of $12.37 per diluted share and a decrease in FFO attributable to common shareholders plus assumed conversions of 5c per diluted share. The items will be excluded from "net income, as adjusted" and "FFO, as adjusted," Vornado noted.

10:33 EDT Wells Fargo CFO says 38 branches were consolidated in Q2

10:27 EDT Wells Fargo sees FY19 expenses at high-end of guidance range

10:19 EDT Raytheon submits Lower Tier Air and Missile Defense Sensor proposal to U.S. Army - Raytheon Company announced the submission of its Lower Tier Air and Missile Defense Sensor proposal to the U.S. Army as part of the competition for a new air and missile defense radar. Raytheon's LTAMDS solution is a simultaneous 360-degree, Active Electronically Scanned Array radar powered by Raytheon-manufactured Gallium Nitride, a substance that strengthens the radar signal and enhances its sensitivity. "Our proposal offers the Army a brand-new radar that overmatches the future threat," said Tom Laliberty, Raytheon Vice President of Integrated Air and Missile Defense. "We brought our LTAMDS solution to the U.S. Army's sensor demonstration and validated our ability to meet their 2022 urgent material release date."

10:08 EDT Evelo Biosciences Inc trading halted, volatility trading pause

10:03 EDT Allakos treatment of mastocytosis granted FDA orphan designation - Allakos was granted FDA orphan designation for its treatment of mastocytosis, according to a post to the agency's website. Reference Link

10:00 EDT Heritage Insurance falls -5.6% - Heritage Insurance is down -5.6%, or -90c to $15.05.

10:00 EDT VelocityShares 3x Long Natural Gas ETN falls -8.6% - VelocityShares 3x Long Natural Gas ETN is down -8.6%, or -$1.55 to $16.44.

10:00 EDT VelocityShares 3x Inv Natural Gas ETN rises 8.3% - VelocityShares 3x Inv Natural Gas ETN is up 8.3%, or $11.52 to $150.52.

09:58 EDT Rekor Systems reports joining NVIDIA Metropolis Software Partner Program - Rekor Systems (REKR) announced earlier that the company has joined the NVIDIA Metropolis Software Partner Program and "is leveraging NVIDIA Graphic Processing Units to accelerate its OpenALPR vehicle recognition software." NVIDIA (NVDA) Metropolis is an intelligent video analytics platform that spans multiple NVIDIA products operating on a unified architecture, Rekor stated. Rekor shares are up 18c, or 7.6%, to $2.55 in early trading.

09:51 EDT Goldman Sachs CFO says bank had $375M gain in Q2 from Tradeweb IPO

09:48 EDT Immuron jumps after reporting FY19 sales of A$2.6M - Immuron announced earlier sales results for the year ended June 30 for its commercially available products, including Travelan, the over-the-counter gastrointestinal and digestive health supplement. Travelan sales in North America in FY19 rose 52% and reached A$1.16M. Global Immuron revenue expanded by 29% year-over-year in FY19, reaching A$2.6M. "During the 2019 fiscal year, Immuron added to the ongoing successful efforts in Australia by working hard to increase awareness of Travelan amongst North American consumers, using podcasts and collaborations with travel bloggers to educate and inform the market regarding the virtues of our product. The new 2020 fiscal year will see our efforts ramp-up even further in North America as we expand distribution channels and work to further consumer demand in that very important geographic area using pull-through marketing campaigns and other forms of advertising," said CEO Gary Jacob. In early trading, Immuron shares are up $2.88, or 98%, to $5.81.

09:47 EDT Lear falls -6.3% - Lear is down -6.3%, or -$8.53 to $126.75.

09:47 EDT VelocityShares 3x Long Natural Gas ETN falls -9.3% - VelocityShares 3x Long Natural Gas ETN is down -9.3%, or -$1.68 to $16.31.

09:47 EDT VelocityShares 3x Inv Natural Gas ETN rises 9.2% - VelocityShares 3x Inv Natural Gas ETN is up 9.2%, or $12.73 to $151.73.

09:45 EDT Goldman Sachs CEO says will provide new financial targets in January

09:27 EDT JMU receives Nasdaq letter of deficiency - JMU announced it received a letter from Nasdaq notifying the Company that it does not meet the continued listing requirements for the stockholders' equity as reported in the Company's annual report on Form 20-F for the period ended December 31, 2018 is below the minimum amount of $10M as required for continued listing under the equity standard, the market value of listed securities of the Company is below $50M as required for continued listing under the market value standard, and the market value of publicly held shares is below $15M as required for continued listing under both the market value and the total assets/total revenue standards. The Company must submit its Compliance Plan no later than July 22. The Company is working diligently to prepare the Compliance Plan and expects to submit it to Nasdaq within this timetable. If the Compliance Plan is accepted, the Company can be granted an extension of up to 180 calendar days from the date of the Notification Letter to evidence compliance.

09:22 EDT Ideanomics forms a New Energy Transportation Services Group - Ideanomics announced the formation of New Energy Transportation Services Group, or NETS, a service company proving comprehensive and commercial solutions that include Marketing, Financial Services, Technology and Infrastructure for the New Energy Transportation Services industry with. This newly-formed group will be domiciled in Singapore to embrace the global business ex-China, beginning with Malaysia and the other ASEAN countries. From Asean, the company plans to expand its substantial commercial offerings into other regions, including North America and Europe, to develop and support cleantech commercial vehicle markets. The NETS Group is focusing its full-service model of 'Sales-to-Financing-to-Charging networks in efforts to support the full value chain of the cleantech commercial vehicle industry.

09:19 EDT Fulgent Genetics, Parkinson's Foundation partner on genetic testing initiative - Fulgent Genetics and the Parkinson's Foundation announced a collaboration on a new genetic testing initiative for individuals living with Parkinson's Disease. The nation-wide initiative, called PD GENEration: Mapping the Future of Parkinson's Disease, provides genetic testing for clinically relevant Parkinson's-related genes for eligible individuals. The initiative will be offered through the Parkinson's Foundation Centers of Excellence network and Parkinson Study Group sites, and it will leverage the next generation genetic testing technology of Fulgent Genetics. As part of the collaboration agreement, Fulgent Genetics will be compensated for processing, sequencing, and storing each DNA sample for patients participating in the initiative. Also supporting this initiative are Indiana University School of Medicine, providing genetic counseling for tested individuals; University of Florida CTSI Data Coordinating Center, assisting with secure data storage; and University of Rochester's Clinical Trials Coordination Center. In collaboration with these partners, Fulgent Genetics has leveraged the flexibility of its broad testing catalog to select and develop a targeted list of seven genes relevant to Parkinson's patients and clinicians: GBA, LRRK2, SNCA, PRKN, PARK7, VPS35, and PINK1. Fulgent Genetics will analyze and generate clinical reports for these target genes, and the findings will be made available to the treating physicians and future researchers.The initiative aims to enroll 600 participants in its first year of operation, expanding to include 15,000 participants by 2024.

09:17 EDT Hill International to provide program management for The Port of Long Beach - Hill International announced it has been awarded a contract to support the management of the Port of Long Beach's Pier B On-Dock Rail Support Facility program. The 14-year program, which the Port calls the "centerpiece" of its $1B rail improvement program, will reconfigure and expand the existing Pier B Rail Yard to support the increased use of on-dock rail in the harbor. Each on-dock rail will save approximately 750 truck trips between the Port and off-dock rail yards. Moving more containers by rail will also help the Port's marine terminals transfer cargo more efficiently and help achieve the environmental goals in the Port's Clean Air Action Plan.

09:12 EDT Land and Buildings issues letter to Brookdale Senior Living shareholders - Land and Buildings issued the following open letter to shareholders of Brookdale Senior Living: "... We remain deeply disappointed that the Board does not appear to recognize the need for urgent and real change at Brookdale. Brookdale's total shareholder return has consistently underperformed relative to Proxy Peers, Healthcare REITs, and the broad market over the trailing 10-year, 5-year, 3-year, and 1-year time periods. Since Cindy Baier and Lee Wielansky were appointed CEO and Chairman of the Board respectively in February 2018, this trend has not reversed. We are deeply disappointed and fault a lack of urgency on the part of the Company, having not sought to maximize value for all shareholders through an asset monetization program since the majority of leases were restructured more than a year ago. To that end, on July 2, 2019, we nominated two director candidates for election to the Board at the Company's 2019 Annual Meeting of Shareholders. We believe our nominees have the deep healthcare, real estate and finance experience necessary to help properly evaluate the best ways to maximize value for all Brookdale shareholders, including evaluating the best strategic options for Brookdale's real estate and capital structure. Our highly qualified nominees include: Jay Flaherty - Former CEO and Chairman of healthcare REIT HCP and experienced healthcare real estate investor and board member. Jonathan Litt - Founder/CIO of Land and Buildings and former top-ranked sell-side REIT analyst. Despite the Company's promise "to evaluate Land & Buildings' nominees," as stated in an 8-K filed July 3, 2019, we are disappointed the Nominating and Corporate Governance Committee has not engaged with our two nominees to date. In addition to the appointment of Messrs. Flaherty and Litt to the Board, Land & Buildings believes Brookdale's Investment Committee should be tasked with evaluating all strategies to maximize the value of the Company's real estate, including outright asset sales as well as separating the real estate from the management company into two separate public companies. The Investment Committee should include Land & Buildings' two nominees.Land & Buildings has engaged Green Street Advisors, a leading independent real estate research and advisory firm, to value the Company and its real estate, as well as opine on the feasibility of a PropCo/OpCo split. Green Street's preliminary results based on publicly available information are encouraging: the net asset value (NAV) of Brookdale is substantially above the current share price and there may be several options, including viable OpCo/PropCoREIT structures that could lead to a near doubling of the share price from recent trading levels. We believe the Company's prior concerns about a REIT structure can be straightforwardly addressed while creating substantial value for shareholders... Our continued preference is to reach a collaborative agreement with the Company that includes the items outlined in this letter so that value can be maximized in an expedient manner and without distraction. However, if our concerns continue to fall on deaf ears, we will have no choice but to hold this Board accountable. Brookdale should be run for the benefit of shareholders, not management, the Board, or the three large REIT landlords, which necessitates including new Board members steeped in real estate."

09:11 EDT ADT Inc. settles lawsuit filed against NorthStar for $3M - ADT announced it settled a deceptive sales practices lawsuit filed against NorthStar Alarm Services for $3M. As part of the settlement, NorthStar agreed to a $5M consent judgment if the company defaults on paying the $3M settlement. As part of its case, ADT provided evidence from at least 500 customers stating they were victims of deceptive sales tactics from NorthStar employees over the past five years. This latest legal accomplishment comes less than two months after a South Florida jury awarded ADT $4M in damages, including $1M in punitive damages, in a similar deceptive sales lawsuit against Alder Holdings.

09:09 EDT Marlin, Waterplay form partnership for financing program - Marlin and Waterplay announced a partnership to provide financing options for Waterplay customers. Marlin's financing options will be available to Waterplay's customers through its direct sales channel and authorized distributors. The strategic alliance will enable Waterplay's municipal and commercial customers to invest in the company's extensive range of products through Marlin's fast, convenient automated approval and documentation process.

09:07 EDT abercrombie kids, Nickelodeon partner for #PlayIsLife campaign - abercrombie kids, a division of Abercrombie & Fitch (ANF), is partnering with global entertainment brand, Nickelodeon (VIA, VIAB), to make the world a more playful place through its #PlayIsLife campaign, marking Nickelodeon's first branded content partnership with a retail brand. This integrated collaboration aims to provide children with play-spiration through three elements: limited-time merchandise, an in-store experience in California, and a series of custom content on Nickelodeon's YouTube channel featuring dancer/actress Nicole Laeno and Gabe and Garrett, stars of the self-titled YouTube channel. The first video launched on July 14, with subsequent ones launching on July 28 and September 1, 2019. The abercrombie kids x Nickelodeon custom tee, which features a Nickelodeon-inspired "slimed" moose, will be available in U.S. stores and online for a limited time starting July 18. The influencers featured in the video series will support the campaign on- and off-screen through social media content and an appearance at an in-store event; on July 20, Nicole will visit the South Coast Plaza abercrombie kids store for a fan meet-and-greet, which will include a DIY jacket station, games and more.

09:04 EDT Canadian Pacific CEO says 'we saw revenue growth across every line of business' - "This quarter, we saw revenue growth across every line of business, strong operating metrics, and our best-ever second-quarter performance from a workload perspective, as measured by Gross Ton-Miles," said CEO Creel. "As has been proven time and again, our operating model can perform well in all economic conditions and we will remain disciplined in controlling our costs and doing what we said we would do. Our strategy for sustainable, profitable growth is working and we look forward to a strong finish to 2019."

09:03 EDT JPMorgan CEO Dimon says not feeling heat from Facebook's Libra - Jamie Dimon said: "We've been talking about blockchain for seven years now and very little has happened and you're going to be talking about Libra three years from now." "I wouldn't spend too much time on it," he said, adding that "We don't mind competition but the request is to be treated the same."

09:01 EDT Lockheed Martin to produce HIMARS launchers for U.S. Army - Lockheed Martin will produce High Mobility Artillery Rocket System, or HIMARS, launchers and associated hardware for the U.S. Army, U.S. Marine Corps, Romania and Poland under a $492 million contract, marking Poland's first acquisition of HIMARS launchers. The contract calls for the production and delivery of HIMARS launchers and associated equipment by 2022. The HIMARS vehicles will be produced from the ground up at Lockheed Martin's award-winning Camden, Ark., Precision Fires Center of Excellence.

08:57 EDT Neovasc expects to launch its Reducer in 2020 if approved by FDA - Neovasc provided a further update on its Neovasc Reducer program for the treatment of refractory angina. As previously announced, following guidance recently received from the FDA, Neovasc intends to seek the FDA's designation of the Reducer as a HUD for CCS Class IV refractory angina patients. If it is possible and if the FDA grants HUD designation for the Reducer for CCS Class IV patients, and if a subsequent HDE application is approved by the FDA as well, Neovasc expects to begin commercializing the Reducer in the U.S. by early 2020.

08:51 EDT Johnson & Johnson says Q2 results 'in-line with expectations' - Says expects to deliver competitive growth relative to the market for the full year. Comments from company's Q2 earnings conference call.

08:50 EDT CV Sciences announces new production, warehouse facility in San Diego - CV Sciences announced the expansion of its operations with a new production and warehouse facility. The 45,500 square foot facility will expand the Company's capacity for hemp CBD oil production, warehousing and fulfillment by more than 500 percent to meet growing retailer and consumer demand for PlusCBD Oil products. The facility, located in San Diego, is expected to be operational in the fourth quarter of 2019 and will support CV Sciences' U.S. and international expansion opportunities. On July 10, 2019, CV Sciences announced the commencement of its domestic hemp sourcing initiative, including a commitment to more than 500 acres of U.S.-based hemp production for 2019. This new supply of U.S. produced hemp-based CBD will be extracted through CV Sciences' domestic supply chain partners and refined at the Company's San Diego production facilities, broadening the Company's global supply chain and raw material supply while reducing transportation and logistics costs.

08:45 EDT JPMorgan CFO says sees up to three rate cuts this year

08:41 EDT Document Security appoints Jason Grady as COO - Document Security Systems announced that Jason Grady has been appointed COO, effective immediately. For the past year, Grady has served as president of the company's packaging and printing division, Premier Packaging Corp. As COO of DSS, Grady will provide his leadership, management and vision to guide the organization in the execution of growth-focused strategies and product development.

08:39 EDT Gilead subsidiary Kite announces plans for viral vectors facility in California - Kite, a Gilead company, announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a "critical" starting material in the production of cell therapies. The new site builds on Kite's existing manufacturing capabilities to deliver cell therapies for people with cancer, including Yescarta, Kite's first commercially available chimeric antigen receptor T cell therapy, and investigational T cell receptor and tumor neoantigen targeting cell therapies being evaluated in solid tumors. Kite's facility will be constructed within an existing Gilead biologics operations facility in Oceanside and will become part of Kite's commercial manufacturing network that includes sites in California, Maryland and the Netherlands.

08:38 EDT JPMorgan CFO says doesn't see signs of broad-based deterioration in portfolio - CFO Jennifer Piepszak says does not see any signs of broad-based deterioration across portfolios, both Consumer and Wholesale. Comments taken from Q2 earnings conference call.

08:37 EDT Iteris receives $2.95M additional task order funding from FHWA - Iteris announced that it has received an additional $2.95M in funding for a task order under its indefinite delivery/indefinite quantity, or IDIQ, contract from the Federal Highway Administration, or FHWA, to provide continued development, evolution and deployment support for the intelligent transportation system, or ITS, reference architecture program. Under the three-year task order agreement, which was initiated in June 2018 and is part of a five-year IDIQ contract with a contract ceiling of up to $19.5M, Iteris will support the evolution of the Architecture Reference for Cooperative and Intelligent Transportation, or ARC-IT, content to reflect changes in ITS, and connected and automated vehicle, or CAV, developments. The program supports statewide and regional ITS planning and deployment to encourage interoperability and CAV preparedness through workshops, training and technical assistance. An important aspect of the program is alignment with and support for standards development activities, as well as international coordination of ITS architecture and standards concepts and approaches.

08:35 EDT Moody's to sell MAKS business to Equistone Partners Europe - Moody's announced that it has agreed to sell its Moody's Analytics' Knowledge Services, or MAKS, business to Equistone Partners Europe, a European private equity firm. The transaction is expected to close later this year, subject to customary closing conditions. It is expected to be dilutive to Moody's EPS on a GAAP basis in full-year 2019 by up to 20c per share, mainly due to certain non-recurring charges associated with the transaction, which will be finalized at closing. On an adjusted EPS basis, excluding the aforementioned non-recurring charges, the impact to FY19 results will be negligible. It is anticipated that sale proceeds and repatriated offshore cash will be used to repurchase approximately $300M of Moody's outstanding stock.

08:34 EDT Medipharm to rollout distribution of products to remaining provinces in 2H19 - The company said, "During the quarter, MediPharm Labs became the only third-party concentrate manufacturer to begin shipping white label products, including bottled oil, to Provincial cannabis distributors. MediPharm Labs' white label products can be found in three provinces including Ontario, British Columbia and Alberta. The Company expects to rollout distribution of Health Canada approved products to all remaining provinces during H2 2019. MediPharm Labs successfully completed its first international export of commercial volume cannabis concentrate to AusCann in Australia in June 2019. The Company continues to focus on accessing and distributing its private label cannabis concentrate to global markets, including across Europe, and is working on various commercial terms."

08:32 EDT Medipharm Labs acquired 9,000 KG of dried cannabis at end of June - The company said, "The number of dry cannabis suppliers and concentrate purchasers in Canada continues to increase. In turn, this has resulted in higher demand that supports MediPharm Labs' differentiated, private label business model.The Company announced it successfully acquired 9,000 KG of dried cannabis in the last three weeks of June 2019 expected to be processed and sold in Q3 2019, and 5,000 KG in the last two weeks of March 2019 that were processed and sold in Q2 2019."

08:30 EDT Medipharm increases production of private label cannabis concentrate products - MediPharm Labs has increased production of private label cannabis concentrate products and distillate supply - including CBD or THC dominant as well as balanced formulations - to meet the growing demand for specialty concentrate based consumer end products ahead of legalization of vapeables, edibles and topicals in the fall of 2019. Production and quality operations teams ramped up weekly production output to approximately 75 million milligrams of active cannabinoid component concentrate at the end of Q2 2019. To date, MediPharm Labs has signed four significant contracts for the sale of private label cannabis concentrate. The Company also launched its White Label platform to service direct-to-consumer brands, CPG companies and large LPs in Canada. In June 2019, MediPharm announced its first white label deal to produce a minimum of approximately two million vape pens with Ace Valley, subject to purchase orders from provincial distributors.

08:29 EDT Medipharm CEO says 'executing exceptionally well' against strategic priorities - "MediPharm Labs is executing exceptionally well against all of our strategic operating priorities for 2019 and this will be reflected in our financial results for Q2 and beyond," said CEO Patrick McCutcheon." I am particularly pleased with the pace of new sales, the advancements we're making in scaling up global production and the high-quality collaborations underway with industry Health Canada compliant suppliers, customers and scientific partners. I am confident that our recent momentum will continue as we strive to produce the world's best cannabis concentrates and drive future cannabis product innovation."

08:26 EDT Blue Apron jumps after saying Beyond Meat burgers are coming in August - Shares of from Blue Apron (APRN) are moving higher after the company announced that plant-based proteins from Beyond Meat (BYND) will be included on its "Signature Two-Serving Plan" starting in August. Consumers can begin placing orders for new "Blue Apron x Beyond Meat" August recipes now through Blue Apron's website and mobile app, the company said in a statement. Recipes include caramelized onion and cheddar Beyond burgers with garlic green beans the week of August 19 and jalapeno and goat cheese Beyond burgers with corn on the cob the week of August 26. "We know a growing number of customers are interested in plant-based proteins, whether as an alternative to meat, a desire to explore a new ingredient, or an opportunity to make more sustainable food choices," said Linda Kozlowski, CEO of Blue Apron. Shares of Blue Apron are up 7% to $8.20 in premarket trading while Beyond Meat is up 1% to $167.60.

08:22 EDT B. Riley Financial appoints Mimi Walters to board of directors - B. Riley Financial announced the appointment of Mimi Walters to the Company's Board of Directors, effective July 12, 2019. Ms. Walters brings significant business, finance and policy expertise with more than 20 years of public service and private sector experience. The appointment of Ms. Walters brings the number of Directors on the Company's Board to nine, of which six are independent. As Director, she will also serve on the Board's Governance Committee. Walters is a former U.S. Representative from California's 45th Congressional District.

08:19 EDT Allscripts selected by St. Luke's Medical Center as EHR - St. Luke's Medical Center has selected Allscripts Sunrise Acute Care as its electronic health record, or EHR, to achieve the goal of standardization across its facilities via a single, integrated EHR. St. Luke's Medical Center is recognized as a healthcare institution in the Philippines, having a total of 1,146 rooms with its Quezon City and Global City sites.

08:17 EDT Mereo BioPharma appoints Richard Francis as head of pharmaceutical development - Mereo BioPharma announces the appointment of Richard Francis as Head of Pharmaceutical Development, effective August 1, 2019. Prior to joining Mereo BioPharma, Francis was the owner and senior director of Francis Biopharma, where he served as an expert CMC consultant to over 30 biopharmaceutical clients, including Mereo.

08:14 EDT Avaloq integrates OneSpan solutions into cloud-based banking platform - OneSpan announced that Avaloq has integrated OneSpan solutions into its cloud-based banking platform. These integrations make it faster and more convenient for banks to connect OneSpan's anti-fraud solutions to their core banking systems using open APIs to secure access, transactions and identities. OneSpan's solutions now form part of Avaloq's overall authentication solution and are integrated into Avaloq's platform. OneSpan's integration allows banks to easily add mobile authentication, transaction signing and multifactor authentication.

08:10 EDT Seattle Genetics, Astellas Pharma announce submission of enfortumab vedotin BLA - Seattle Genetics (SGEN) and Astellas Pharma (ALPMY) announced submission of a biologics license application for accelerated approval to the FDA for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology. Enfortumab vedotin is an investigational antibody-drug conjugate that targets Nectin-4, a protein that is highly expressed in urothelial cancers.

08:08 EDT Spero Therapeutics announces $5.9M award from DoD to develop SPR206 - Spero Therapeutics announced that it has received a $5.9M award from the U.S. Department of Defense Congressionally Directed Medical Research Programs Joint Warfighter Medical Research Program The U.S. Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD 21702- 5014 is the awarding and administering acquisition office. The funding will support the further clinical development of SPR206, Spero's intravenous-administered product candidate from its Potentiator Platform that is being developed as an innovative alternative option to treat MDR Gram-negative bacterial infections. The award commits non-dilutive funding of $5.9M over a four-year period to cover the costs of select Phase 1 pharmacology studies, a 28-day GLP non-human primate toxicology study, and microbiological surveillance studies that would be required for a potential New Drug Application submission with the U.S. Food and Drug Administration for SPR206. In preclinical studies, SPR206 has demonstrated activity as a single agent against MDR and extensively drug resistant bacterial strains, including isolates of Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae, in both in vitro and in vivo models of infection. SPR206 is currently being evaluated in a first-in-human Phase 1 clinical trial, designed as a double-blind, placebo-controlled, single and multiple ascending dose, multi-cohort study in healthy subjects. Spero expects to report top-line data from this trial in the second half of 2019.

08:07 EDT Vermillion announces publication of Overa comparative study results - Vermillion announced publication of a paper in the journal Advanced Therapeutics. The study of 993 patients with 245 malignancies shows that Vermillion's second generation multivariate index assay, Overa, had superior sensitivity to the current standards of care, Risk of Malignancy Algorithm, or ROMA, and CA125, in detecting ovarian cancer, and the lowest false-negative rate in correctly characterizing ovarian malignancy risk. Overa exhibited a statistically significant higher sensitivity of malignancy detection than either ROMA or CA125, with the current ACOG guidance cutoff of 200 U/ml. Overa also outperformed CA125 in detection of combined early stage cancer with a sensitivity of 90.5% for Overa and a sensitivity of 63.1% for CA125. Overa sensitivity also tended to outperform ROMA in detection of combined early stage cancer. Overa also tended to exhibit higher sensitivity than CA 125 and ROMA regardless of cancer type. Overa exhibited a higher non-epithelial cancer sensitivity of 75% compared with 50% for ROMA, and 37.5% for CA125. This gap is significant as non-epithelial cancers are more prevalent in disparate populations. Out of the 245 malignancies Overa exhibited the lowest rate of false negatives compared with CA125 or ROMA. As compared to CA125 and ROMA, Overa exhibited the highest sensitivity according to menopausal status. Overa also had identical sensitivity for pre- and post-menopause.

08:07 EDT Middleby acquires Packaging Progressions, terms not disclosed. - Middleby announced the acquisition of Packaging Progressions. Based in Souderton, PA, the company has $30M in annual revenues. Additional terms were not disclosed.

08:06 EDT Outlook Therapeutics doses first patient in second Phase 3 trial for ONS-5010 - Outlook Therapeutics announced that it has dosed the first patient in the ONS-5010-002 Phase 3 clinical trial. ONS-5010-002 is the second of the Company's two required adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab for wet AMD. The study is expected to enroll a total of at least 220 patients at sites in the United States. Patients enrolled in the ONS-5010-002 study will be treated for 11 months. The endpoint for the study is a mean increase in baseline visual acuity of at least five letters at 11 months for ONS-5010 dosed on a monthly basis compared to ranibizumab dosed using the approved alternative dosing regimen of three monthly doses followed by quarterly dosing. Full enrollment for ONS-5010-002 is expected in the fourth quarter of calendar 2019. If the ONS-5010 clinical program is successful, it will support the Company's plan to submit for regulatory approval in multiple markets in 2020. If approved, ONS-5010 has potential to mitigate risks associated with off-label use of Avastin or other drugs. Off label use of Avastin is currently estimated to account for at least 50% of all wet AMD prescriptions in the United States.

08:05 EDT Soliton submits pivotal cellulite clinical trial protocol for IRB approval - Soliton announced that the company has submitted its pivotal cellulite clinical trial protocol for independent Institutional Review Board, or IRB, approval.

08:04 EDT scPharmaceuticals expects to resubmit FUROSCIX NDA by mid-year 2020 - scPharmaceuticals announced it received minutes from the Type C Guidance Meeting held on June 18, 2019, between the Company and the U.S. Food and Drug Administration, to discuss the Company's New Drug Application for FUROSCIX, scPharmaceuticals' lead program for the treatment of congestion in patients with heart failure. As an outcome of the meeting, the FDA confirmed that it does not believe it will be necessary to conduct additional clinical safety, efficacy, or pharmacology studies as part of scPharmaceuticals' NDA for FUROSCIX. The FDA further provided recommendations on the Company's proposed device verification and validation plan for the FUROSCIX Infusor, which is currently underway. The FUROSCIX Infusor is West Pharmaceutical Services, SmartDose drug delivery system integrated with FUROSCIX. As a result of the Type C Meeting, scPharmaceuticals is accelerating its timeline and now expects resubmission of the FUROSCIX NDA with the FDA by mid-year 2020.

08:03 EDT Wells Fargo reports Q2 total average lowns $947.5B, down $2.6B from Q1

08:03 EDT Nielsen moves TV ratings platform to AWS - Nielsen (NLSN) announced that as part of an ongoing initiative to transform the technology infrastructure that powers its products and services, it has migrated its core National Television Audience Measurement processing from traditional on-premise server processing to a cloud-based infrastructure. These assets serve as the foundation for the industry currency, underpinning over $70B dollars in advertising revenue in the U.S. annually. Working alongside with Amazon Web Services (AMZN), this major initiative provides Nielsen with the key foundation to improve scalability, redundancy and reliability, which has never been more crucial in an industry that has seen the rapid advancement of technical capabilities and innovation.

08:02 EDT LogicBio Therapeutics receives rare pediatric disease designation for LB-001 - LogicBio Therapeutics announced the U.S. Food and Drug Administration has granted rare pediatric disease designation to LB-001, a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase gene for the treatment of methylmalonic acidemia. In addition to rare pediatric disease designation, LogicBio previously received orphan drug designation from the FDA for LB-001.

07:55 EDT Gridsum trading halted, news pending

07:47 EDT Capitala Group exits Xirgo Technologies, US Bath Group - Capitala Group announced that it has exited Xirgo Technologies, and US Bath Group, which does business as MPL Company. On June 13, 2019, the Company exited its $15.8M subordinated debt investment at par in Xirgo, M2M communication platforms used to track, monitor, protect and control remote assets. Capitala continues to hold its minority equity investment. On June 18, 2019, the Company exited its investment in US Bath, a manufacturer of engineered composite products primarily for the hotel industry. Proceeds from the exit totaled $16.7M; $12.4M for full repayment of its senior secured debt at par, and $4.3M for its equity investment.

07:37 EDT Melinta Therapeutics says FDA accepted Baxdela sNDA for priority review - Melinta Therapeutics provided a corporate update for the second quarter ended June 30, 2019. On July 10, The World Health Organization added Vabomereto its Essential Medicines List for its ability to target multidrug-resistant infections caused by pathogens deemed a "critical priority" by the WHO, including carbapenem-resistant Enterobacteriaceae. The U.S. Food and Drug Administration recently accepted for priority review a supplemental New Drug Application for Baxdela seeking to expand the current indication to include adult patients with community-acquired bacterial pneumonia; the FDA has assigned a Prescription Drug User Fee Act action date of October 24, 2019. Sixteen scientific presentations and posters of portfolio and pipeline data have been accepted for presentation at the Infectious Diseases Society of America IDWeek 2019 meeting and at the American College of Chest Physicians CHEST Meeting.

07:35 EDT Domino's Pizza CEO says Q2 'good, particularly for global unit growth' - "It was a good second quarter, particularly for global unit growth, as we continue to seek balanced retail sales growth through the blend of same store sales and store growth," said Ritch Allison, Domino's CEO. "As a work-in-progress brand, we are constantly striving to improve in needed areas, execute our long-term strategy and build toward Dominant #1 - a goal I continue to feel we are built to achieve."

07:32 EDT Goldman Sachs returned $1.57B of capital to shareholders in Q2

07:31 EDT Domino's Pizza reports Q2 U.S. same store sales growth of 3.0% - Report Q2: International same store sales growth of 2.4%; Global net store growth of 200.

07:26 EDT CURE Pharmaceutical receives patent on oral thin films with bi-phasic release - CURE Pharmaceutical announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. The patent expands on CURE's proprietary drug delivery system, CUREfilm to include bi-phasic release of natural active ingredients with the potential for increasing the overall drug load while retaining a rapid dissolution profile.

07:16 EDT Akcea Therapeutics, Ambry Genetics expand hATTR Compass partnership - Akcea Therapeutics (AKCA), an affiliate of Ionis Pharmaceuticals (IONS), and Ambry Genetics, a Konica Minolta company (KNCAY), announced an expansion of their collaboration as the two companies mark the one-year anniversary of the hATTR Compass program. hATTR Compass is a no-cost, confidential genetic testing and genetic counseling program for people with suspected hereditary amyloidosis that enables faster diagnosis and earlier treatment of this rare, progressive and fatal disease. To date, over 700 physicians across the United States, Canada and Puerto Rico have utilized hATTR Compass to help hundreds of people learn if they carry any of the TTR gene mutations associated with hATTR amyloidosis. Akcea and Ambry recently expanded their hATTR Compass partnership which includes increasing their salesforce and marketing efforts to drive additional awareness and education for patients and physicians.

07:09 EDT Aptose Biosciences doses third cohort in Phase 1 study of APTO-253 - The company has completed the first two dose levels of the Phase 1b clinical trial of MYC inhibitor APTO-253, and is now dosing the third dose cohort. Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemiaand myelo dysplastic syndrome.

07:07 EDT Alnylam enters collaboration with 23andMe - Alnylam Pharmaceuticals and 23andMe are collaborating on a program to offer free 23andMe Health + Ancestry kits to first-degree family members of 23andMe customers with a TTR variant detected in their Hereditary Amyloidosis Genetic Health Risk report. The disease, called TTR-related hereditary amyloidosis, is a genetic condition caused by the buildup of a protein called transthyretin, or TTR, in the body's tissues and organs. This protein buildup, called amyloidosis, can damage the nerves, the heart, and other parts of the body.

07:05 EDT KKR appoints Emilia Sherifova as chief information and innovation officer - KKR announced the appointment of Emilia Sherifova as member and chief information and innovation officer, effective immediately. In this role, Sherifova will be based in New York and will drive KKR's technology and data innovation vision and strategy. Sherifova joins KKR from Northwestern Mutual where she led the company's digital transformation in the role of CTO and previously as head of enterprise architecture and engineering.

07:04 EDT Spirit MTA files preliminary proxy statement regarding proposed sale of assets - Spirit MTA REIT (SMTA) said it has filed a preliminary proxy statement with the U.S. SEC related to its agreement to sell its Owned Properties held in the Company's Master Trust 2014 and three assets presently owned by Spirit Realty Capital, Inc. to Hospitality Properties Trust (HPT) for $2.4B in total cash consideration, subject to certain adjustments, as previously announced on June 3, 2019. The closing of the transaction is subject to customary conditions, including the receipt of the approval of SMTA shareholders. SMTA also announced that, through July 12, 2019, the company has recovered approximately $24M on the Shopko B-1 Term Loan. While there can be no assurances that the company will recover all remaining amounts due under the Term Loan, the company intends to continue to pursue all of its rights and remedies in connection with Shopko's bankruptcy proceedings. After a comprehensive marketing effort undertaken since January 2019, the company also entered into a purchase agreement for the sale of its distribution center, owned by a subsidiary of the Company, Spirit AS Katy TX, LP, and leased to Academy Sports + Outdoors, for a gross purchase price of $94M. The net proceeds to be received by SMTA from the sale, after accounting for transaction and loan assignment and assumption expenses, is approximately $10M. In addition to the satisfaction of ordinary course real estate transaction conditions, the closing of the sale is contingent upon obtaining lender's approval for buyer's assumption of the outstanding CMBS debt encumbering the property, and release of SMTA and its subsidiary from all further obligations under the loan.

07:03 EDT China Lending receives delisting determination letter from Nasdaq - China Lending announced that on July 11 the Company received a delisting determination letter from Nasdaq Listing Qualifications, indicating that the Company's securities would be subject to delisting from the Nasdaq Capital Market based on its non-compliance with the continued listing requirements, unless the Company timely requests a hearing before the Nasdaq Hearings Panel. As previously announced, on May 1 the Company received a notification letter from Nasdaq notifying that the Company is no longer in compliance with the Nasdaq Capital Market's continued listing requirement of a minimum of $2,500,000 in stockholders' equity. The Company submitted a draft plan to regain compliance and supplementary supporting materials. However, after reviewing the submission, Nasdaq has determined that the draft plan, together with the supporting materials, is not sufficiently definitive to evidence the Company's ability to achieve near term compliance with the continued listing requirements or sustain such compliance over an extended period of time. The Company has requested a hearing before the Panel to appeal the delisting determination. The hearing request has stayed the delisting action of the Company's securities by Nasdaq pending the Panel's final decision. There can be no assurance that the Panel will grant the Company's request for continued listing.

06:58 EDT JPMorgan sees FY19 adjusted expense of less than $66B - Sees FY19 net charge-offs of about $5.5B. Comments from slides being presented on the Q2 earnings conference call.

06:54 EDT JPMorgan reports Q2 book value per share of $73.77, up 7% - Reports tangible book value per share2 of $59.42, up 8%.

06:51 EDT JPMorgan reports Q2 average total loans up 2% y/y, down 1% sequentially - Reports Q2: Average loans down 2%; Home Lending loans down 7% impacted by loan sales; credit card loans up 8%; Client investment assets up 16%; average deposits up 3%; Credit card sales volume6 up 11%; merchant processing volume up 12%.

06:50 EDT JPMorgan reports Q2 average loan balances up 7% - Reports Q2 AUM of $2.2T, up 7%.

06:45 EDT Johnson & Johnson CEO says 'pipelines continue to progress' - "We delivered solid Q2 underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses," said Alex Gorsky, Chairman and CEO. "Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world."

06:32 EDT Immunic appoints Sanjay Patel, CFA, as CFO - Immunic announced the appointment of Sanjay Patel, CFA, as CFO, effective July 15. Patel replaces Tamara Seymour, who has served as the company's Interim CFO since April 26.

06:11 EDT PG&E details progress on wildfire safety efforts - PG&E is working to fix nearly 10,000 problems it discovered throughout its electrical system, the company said on its website. PG&E said it continues to make substantial progress toward its Community Wildfire Safety Program goals, intended to mitigate the risk of wildfires and protect customers and communities. "We've accomplished a lot, but there is more work to do. Our system is better today than it was yesterday, and it will be better tomorrow than it is today. We are committed to further reduce wildfire risks and help keep our customers and the communities we serve safe," said Sumeet Singh, PG&E vice president of the Community Wildfire Safety Program. Updates include: Wildfire Safety Inspection Program: Visual inspections of 96 percent and aerial inspections of 92 percent of approximately 50,000 transmission structures in high fire-risk areas. Inspections of all 222 substations in high fire-risk areas. Inspections of more than 99 percent of nearly 700,000 distribution poles in, or adjacent to, high fire-risk areas. Wildfire Safety Operations Center: The 24/7 command center for PG&E's wildfire monitoring and response opened in 2018. The WSOC, based in PG&E's San Francisco headquarters, has received technological and facility upgrades in 2019. Weather stations. These provide hyper-local information and increase situational awareness. Approximately 430 have been installed since 2018, including 231 so far this year. PG&E will have 600 in place by the end of 2019 and 1,300 by 2022. Reference Link

05:23 EDT Urban Tea receives Nasdaq notification letters regarding delisting, minimum bid - Urban Tea announced that the company has received two notification letters from Nasdaq on July 9 and July 10, notifying the company that it is not in compliance with the minimum Market Value of Listed Securities, or MVLS, requirement and the Minimum Bid Price requirement, respectively. On July 9, Nasdaq sent the company a notification letter stating that the company is not in compliance with the MVLS requirement set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b) requires listed securities to maintain either stockholders' equity of at least $2.5M, a minimum MVLS of $35M or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. Nasdaq Listing Rule 5810(c)(3)(C) provides that a failure to meet a minimum MVLS exists if the deficiency continues for a period of 30 consecutive business days. Based upon Nasdaq's review of the company's MVLS for the last 30 consecutive business days, the company no longer meets the minimum MVLS requirement. The MVLS Deficiency letter does not impact the company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the company has been provided 180 calendar days, or until January 6, 2020 to regain compliance with Nasdaq Listing Rule 5550(b)(2). On July 10, Nasdaq sent the company a second notification letter stating that the minimum bid price per share for the company's ordinary shares has been below $1.00 for a period of 30 consecutive business days and the company therefore no longer meets the Bid Price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The Bid Price Deficiency letter received has no immediate effect on the listing of the company's ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the company has until January 6, 2020 to regain compliance. If at any time during such 180-day period the closing bid price of the company's ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the company written confirmation of compliance. If the company does not regain compliance by curing the Bid Price Deficiency during such 180-day period, the company may be eligible for an additional 180 calendar days, provided that the company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The company intends to promptly evaluate options available to regain compliance. However, there can be no assurance that company will be able to regain compliance with the applicable Nasdaq listing requirements.